Skip to main content

Vir Biotechnology, Inc.

corporate_fare Company Profile

Vir Biotechnology, Inc.

VIR·NASDAQ·Life Sciences·CIK 0001706431

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines for serious infectious diseases and cancer by enhancing the immune system. The company focuses on developing therapies that improve the immune system's ability to overcome evasion tactics used by cancer cells and viruses. Vir Bio's clinical development pipeline includes investigational therapies for hepatitis delta virus (HDV) and multiple solid tumors. For hepatitis delta, the company has initiated its registrational ECLIPSE clinical program, which evaluates the combination of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD). This program consists of three ongoing randomized, controlled trials: ECLIPSE 1, ECLIPSE 2, and ECLIPSE 3. ECLIPSE 1 and ECLIPSE 3 have completed enrollment. Topline results for ECLIPSE 1 are anticipated in the fourth quarter of 2026, while topline results for ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027.

Vir Biotechnology, Inc. (NASDAQ:VIR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for VIR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-10, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VIR spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • Vir Biotech Posts $80.1M Q2 Profit, 88% HDV Clearance in Key Trial
  • Vir Bio Swings to Q2 Profit on Astellas Deal, ECLIPSE Program Fully Enrolled
  • Vir Biotech Q2 Revenue Seen Surging 17,730% to $216M on Astellas Deal
  • Vir Biotechnology CFO Jason O'Byrne Steps Down; CAO Brent Sabatini Named Interim
  • Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$68.56M
Net Income
-$437.99M
Diluted EPS
-$3.16
Op. Cash Flow
-$391.78M
Free Cash Flow
-$396.61M
Gross Profit
$68.53M
Operating Income
-$479.33M
Cash & Equivalents
$232.19M
Debt / Equity
0.00×
Net Margin
-6.39×
Shares Outstanding
139.47M sh
Source: 10-K · filed 2026-02-23 · accession 0001628280-26-010749
Browse all tickers starting with V →
$10.5 -0.10% today
52-week range · as of 2026-08-05 $4.16 – $11.66
Market cap
$1.79B
Volume
7M (3.4× avg)
3-mo avg 2M
Live data · 2026-09-20 12:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VIR - Latest Insights

VIR
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.85
Real-time Price: $10.50 info
Change: +$1.65 (+19%) info
Market Cap: $1.794B info
VIR
Aug 05, 2026, 5:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.71
Real-time Price: $10.50 info
Change: +$0.790 (+8%) info
Market Cap: $1.794B info
VIR
Aug 03, 2026, 6:39 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $9.00
Real-time Price: $10.50 info
Change: +$1.50 (+17%) info
Market Cap: $1.794B info
VIR
Jul 24, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $10.50 info
Change: +$1.12 (+12%) info
Market Cap: $1.794B info
VIR
Jun 10, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.80
Real-time Price: $10.50 info
Change: +$2.70 (+35%) info
Market Cap: $1.794B info
VIR
May 18, 2026, 4:07 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $8.77
Real-time Price: $10.50 info
Change: +$1.73 (+20%) info
Market Cap: $1.794B info
VIR
May 06, 2026, 5:32 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $10.45
Real-time Price: $10.50 info
Change: +$0.050 (+0.48%) info
Market Cap: $1.794B info
VIR
May 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $10.50 info
Change: +$0.350 (+3%) info
Market Cap: $1.794B info
VIR
Apr 10, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $10.50 info
Change: +$1.00 (+11%) info
Market Cap: $1.794B info
VIR
Mar 02, 2026, 9:03 AM EST
Source: Unknown
Importance Score:
7
Price at Filing: $8.86
Real-time Price: $10.50 info
Change: +$1.64 (+19%) info
Market Cap: $1.794B info
VIR
Mar 02, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.79
Real-time Price: $10.50 info
Change: +$1.71 (+19%) info
Market Cap: $1.794B info
VIR
Feb 26, 2026, 5:23 PM EST
Source: Unknown
Importance Score:
8
Price at Filing: $9.25
Real-time Price: $10.50 info
Change: +$1.25 (+14%) info
Market Cap: $1.794B info
VIR
Feb 26, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.31
Real-time Price: $10.50 info
Change: +$1.19 (+13%) info
Market Cap: $1.794B info
VIR
Feb 24, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.12
Real-time Price: $10.50 info
Change: +$1.38 (+15%) info
Market Cap: $1.794B info
VIR
Feb 23, 2026, 5:27 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $11.88
Real-time Price: $10.50 info
Change: -$1.38 (-12%) info
Market Cap: $1.794B info
VIR
Feb 23, 2026, 5:16 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.89
Real-time Price: $10.50 info
Change: -$0.390 (-4%) info
Market Cap: $1.794B info
VIR
Jan 14, 2026, 9:00 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $6.87
Real-time Price: $10.50 info
Change: +$3.63 (+53%) info
Market Cap: $1.794B info
VIR
Jan 12, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.81
Real-time Price: $10.50 info
Change: +$4.69 (+81%) info
Market Cap: $1.794B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets